TrivarX (ASX:TRI) Advances Stabl-Im Brain Cancer Imaging Technology Under New CEO Danielle Meyrick

Sonal Goyal

13 October 2026 11:41 AM AEDT

TrivarX (ASX:TRI) Advances Stabl-Im Brain Cancer Imaging Technology Under New CEO Danielle Meyrick

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

TrivarX appointed Dr Danielle Meyrick as CEO, effective 1 June 2026, to lead its clinical development strategy.
The company is advancing Stabl-Im, an MRI-based imaging platform that uses stable isotopes without radioactive tracers.
Investigational product supply has been secured, while preclinical studies and clinical trial preparations are progressing.
First participant enrolment is targeted for Q1 CY2027, with initial clinical results expected in Q2 CY2027.

TrivarX Limited (ASX:TRI), an Australian healthcare technology company developing diagnostic and medical imaging solutions, is progressing its Stabl-Im platform towards first-in-human clinical evaluation.

The technology combines stable isotope labelling with magnetic resonance imaging (MRI) to investigate biological activity associated with brain cancers and metastases.

Under the leadership of chief executive Dr Danielle Meyrick, who commenced her role on 1 June 2026, the company has prioritised clinical trial preparation, technical validation and regulatory planning.

The development strategy reflects a shift towards oncology imaging, alongside its existing intellectual property relating to mental health diagnostics.

As of 12 October 2026, Stabl-Im remains an investigational technology, with clinical feasibility and diagnostic performance yet to be established in the proposed study.

Danielle Meyrick Brings Clinical Development Experience

TrivarX (ASX:TRI) announced Dr Danielle Meyrick's appointment as chief executive on 29 April 2026, with the appointment becoming effective on 1 June.

Dr Meyrick has more than 20 years of experience across clinical development, radiopharmaceuticals, isotope technologies and oncology.

Her previous positions include Chief Medical Officer for Asia-Pacific and Global Head of Clinical Science at Telix Pharmaceuticals (ASX:TLX).

She also held senior scientific and clinical leadership positions at GenesisCare and ITM Isotope Technologies Munich.

Her responsibilities at TrivarX include overseeing Stabl-Im's clinical development pathway, progressing regulatory engagement and coordinating the technical work required to initiate human studies.

The company has linked certain executive performance incentives to clinical and regulatory milestones, including Phase I development and future regulatory submissions.

These milestones remain subject to successful study execution and the applicable regulatory requirements.

Stabl-Im Technology Targets Non-Radioactive Brain Imaging

Stabl-Im is being developed as a functional imaging platform that uses stable isotopes to provide information about tumour-related cellular activity.

The technology involves deuterium oxide, a non-radioactive isotope-labelled form of water, combined with MRI-based imaging techniques.

The proposed approach aims to provide biological information about cellular proliferation and treatment response without requiring radioactive tracers.

Unlike positron emission tomography, which generally relies on radioactive tracers, Stabl-Im is designed to operate using stable isotope labelling and MRI infrastructure.

One potential application involves distinguishing active tumour growth from treatment-related changes in patients undergoing cancer treatment.

However, the platform has not yet demonstrated sufficient clinical performance to establish that it can reliably distinguish these conditions in routine medical practice.

TrivarX (ASX:TRI) is therefore focused on determining safety, feasibility and imaging performance through controlled clinical evaluation.

Investigational Product Supply and Preclinical Work Progress

TrivarX (ASX:TRI) announced on 16 July 2026 that it had secured the investigational product supply required for its planned clinical feasibility study.

The development followed the appointment of a specialist contract research organisation to support trial protocol preparation, regulatory documentation and clinical site identification.

In its 23 September 2026 update, TrivarX confirmed that preclinical studies had commenced and that preparations for the clinical feasibility study were progressing.

The company also reported the addition of a clinical trial manager to support study initiation and execution.

Further activities include identifying a suitable clinical site, selecting a principal investigator and developing specialised analytical methods for measuring deuterium in biological samples.

Preparations are also underway to ensure the investigational product meets applicable Therapeutic Goods Administration requirements before clinical administration.

Phase I Clinical Trial Timeline Extends Into 2027

TrivarX (ASX:TRI) initially outlined plans to complete its Phase I clinical study during CY2026.

However, its September 2026 development update established a revised timetable extending into CY2027.

The company is targeting completion of preclinical studies in November 2026 and submission of its clinical feasibility study application for ethics review during Q4 CY2026.

An ethics committee determination is anticipated in January 2027.

The first participant is expected to be enrolled during Q1 CY2027, with recruitment completion and initial clinical results targeted for Q2 CY2027.

The planned study will evaluate safety and tolerability associated with controlled deuterium enrichment, alongside preliminary imaging feasibility.

These milestones are indicative and remain dependent on ethics approval, site readiness, technical preparation and participant recruitment.

Key Insights

TrivarX (ASX:TRI) is progressing its Stabl-Im platform towards clinical evaluation under Dr Danielle Meyrick's leadership.

The company's activities during 2026 have centred on investigational product preparation, preclinical studies, clinical protocol development and specialist vendor engagement.

The revised clinical timetable places first participant enrolment in Q1 CY2027 and initial study results in Q2 CY2027.

Although Stabl-Im offers a potential approach to investigating brain tumour activity without radioactive tracers, its clinical utility remains unproven.

Future progress will depend on safety findings, imaging performance, regulatory requirements and the completion of planned clinical studies.

FAQs

Q: What is TrivarX's (ASX:TRI) Stabl-Im technology designed to do?

A: Stabl-Im combines stable isotope labelling with MRI to investigate biological activity associated with brain tumours. The technology is being developed as a potential complementary imaging approach without radioactive tracers.

Q: Who is leading TrivarX's (ASX:TRI) clinical development strategy?

A: Dr Danielle Meyrick became chief executive on 1 June 2026. She previously held senior clinical development positions at Telix Pharmaceuticals (ASX:TLX), GenesisCare and ITM Isotope Technologies Munich.

Q: When does TrivarX (ASX:TRI) expect its Phase I clinical trial milestones?

A: The company is targeting ethics committee determination in January 2027, first participant enrolment during Q1 CY2027 and initial clinical study results during Q2 CY2027, subject to required approvals and study progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.